BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Moise L, Gutierrez AH, Bailey-Kellogg C, Terry F, Leng Q, Abdel Hady KM, VerBerkmoes NC, Sztein MB, Losikoff PT, Martin WD, Rothman AL, De Groot AS. The two-faced T cell epitope: examining the host-microbe interface with JanusMatrix. Hum Vaccin Immunother 2013;9:1577-86. [PMID: 23584251 DOI: 10.4161/hv.24615] [Cited by in Crossref: 66] [Cited by in F6Publishing: 65] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 De Groot AS, Terry F, Cousens L, Martin W. Beyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologics. Expert Rev Clin Pharmacol 2013;6:651-62. [PMID: 24164613 DOI: 10.1586/17512433.2013.835698] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
2 De Groot AS, Moise L, Liu R, Gutierrez AH, Terry F, Koita OA, Ross TM, Martin W. Cross-conservation of T-cell epitopes: now even more relevant to (H7N9) influenza vaccine design. Hum Vaccin Immunother 2014;10:256-62. [PMID: 24525618 DOI: 10.4161/hv.28135] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
3 Liu R, Moise L, Tassone R, Gutierrez AH, Terry FE, Sangare K, Ardito MT, Martin WD, De Groot AS. H7N9 T-cell epitopes that mimic human sequences are less immunogenic and may induce Treg-mediated tolerance. Hum Vaccin Immunother 2015;11:2241-52. [PMID: 26090577 DOI: 10.1080/21645515.2015.1052197] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
4 Losikoff PT, Mishra S, Terry F, Gutierrez A, Ardito MT, Fast L, Nevola M, Martin WD, Bailey-Kellogg C, De Groot AS. HCV epitope, homologous to multiple human protein sequences, induces a regulatory T cell response in infected patients. J Hepatol. 2015;62:48-55. [PMID: 25157982 DOI: 10.1016/j.jhep.2014.08.026] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
5 Bremel RD, Homan EJ. Frequency Patterns of T-Cell Exposed Amino Acid Motifs in Immunoglobulin Heavy Chain Peptides Presented by MHCs. Front Immunol 2014;5:541. [PMID: 25389426 DOI: 10.3389/fimmu.2014.00541] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
6 Bremel RD, Homan EJ. Extensive T-Cell Epitope Repertoire Sharing among Human Proteome, Gastrointestinal Microbiome, and Pathogenic Bacteria: Implications for the Definition of Self. Front Immunol 2015;6:538. [PMID: 26557118 DOI: 10.3389/fimmu.2015.00538] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
7 Jawa V, Joubert MK, Zhang Q, Deshpande M, Hapuarachchi S, Hall MP, Flynn GC. Evaluating Immunogenicity Risk Due to Host Cell Protein Impurities in Antibody-Based Biotherapeutics. AAPS J 2016;18:1439-52. [DOI: 10.1208/s12248-016-9948-4] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 6.2] [Reference Citation Analysis]
8 Richard G, De Groot AS, Steinberg GD, Garcia TI, Kacew A, Ardito M, Martin WD, Berdugo G, Princiotta MF, Balar AV, Sweis RF. Multi-step screening of neoantigens' HLA- and TCR-interfaces improves prediction of survival. Sci Rep 2021;11:9983. [PMID: 33976291 DOI: 10.1038/s41598-021-89016-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Khan S, Parrillo M, Gutierrez AH, Terry FE, Moise L, Martin WD, De Groot AS. Immune escape and immune camouflage may reduce the efficacy of RTS,S vaccine in Malawi. Hum Vaccin Immunother 2020;16:214-27. [PMID: 30614773 DOI: 10.1080/21645515.2018.1560772] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
10 Tucker KD, Schanen BC, Phares TW, Sassano E, Terry FE, Hindocha P, Moise L, Kotraiah V, Martin WD, De Groot AS, Drake DR 3rd, Gutierrez GM, Noe AR. Identification, Selection and Immune Assessment of Liver Stage CD8 T Cell Epitopes From Plasmodium falciparum. Front Immunol 2021;12:684116. [PMID: 34025684 DOI: 10.3389/fimmu.2021.684116] [Reference Citation Analysis]
11 Ahmad TA, Eweida AE, El-sayed LH. T-cell epitope mapping for the design of powerful vaccines. Vaccine Reports 2016;6:13-22. [DOI: 10.1016/j.vacrep.2016.07.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
12 De Groot AS, Desai AK, Lelias S, Miah SMS, Terry FE, Khan S, Li C, Yi JS, Ardito M, Martin WD, Kishnani PS. Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease. Front Immunol 2021;12:636731. [PMID: 34220802 DOI: 10.3389/fimmu.2021.636731] [Reference Citation Analysis]
13 Scholzen A, Richard G, Moise L, Hartman E, Bleeker-Rovers CP, Reeves PM, Raju Paul S, Martin WD, De Groot AS, Poznansky MC, Sluder AE, Garritsen A. Coxiella burnetii Epitope-Specific T-Cell Responses in Patients with Chronic Q Fever. Infect Immun 2019;87:e00213-19. [PMID: 31331958 DOI: 10.1128/IAI.00213-19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
14 Dembele M, Tao S, Massoud AH, Miah SMS, Lelias S, De Groot AS, Mazer BD. Tregitopes Improve Asthma by Promoting Highly Suppressive and Antigen-Specific Tregs. Front Immunol 2021;12:634509. [PMID: 33953711 DOI: 10.3389/fimmu.2021.634509] [Reference Citation Analysis]
15 Eickhoff CS, Terry FE, Peng L, Meza KA, Sakala IG, Van Aartsen D, Moise L, Martin WD, Schriewer J, Buller RM, De Groot AS, Hoft DF. Highly conserved influenza T cell epitopes induce broadly protective immunity. Vaccine 2019;37:5371-81. [PMID: 31331771 DOI: 10.1016/j.vaccine.2019.07.033] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
16 De Groot AS, Moise L, Terry F, Gutierrez AH, Hindocha P, Richard G, Hoft DF, Ross TM, Noe AR, Takahashi Y, Kotraiah V, Silk SE, Nielsen CM, Minassian AM, Ashfield R, Ardito M, Draper SJ, Martin WD. Better Epitope Discovery, Precision Immune Engineering, and Accelerated Vaccine Design Using Immunoinformatics Tools. Front Immunol 2020;11:442. [PMID: 32318055 DOI: 10.3389/fimmu.2020.00442] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
17 Wada Y, Nithichanon A, Nobusawa E, Moise L, Martin WD, Yamamoto N, Terahara K, Hagiwara H, Odagiri T, Tashiro M, Lertmemongkolchai G, Takeyama H, De Groot AS, Ato M, Takahashi Y. A humanized mouse model identifies key amino acids for low immunogenicity of H7N9 vaccines. Sci Rep 2017;7:1283. [PMID: 28455520 DOI: 10.1038/s41598-017-01372-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
18 Antunes DA, Rigo MM, Freitas MV, Mendes MFA, Sinigaglia M, Lizée G, Kavraki LE, Selin LK, Cornberg M, Vieira GF. Interpreting T-Cell Cross-reactivity through Structure: Implications for TCR-Based Cancer Immunotherapy. Front Immunol 2017;8:1210. [PMID: 29046675 DOI: 10.3389/fimmu.2017.01210] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
19 He L, De Groot AS, Gutierrez AH, Martin WD, Moise L, Bailey-Kellogg C. Integrated assessment of predicted MHC binding and cross-conservation with self reveals patterns of viral camouflage. BMC Bioinformatics 2014;15 Suppl 4:S1. [PMID: 25104221 DOI: 10.1186/1471-2105-15-S4-S1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
20 He L, De Groot AS, Bailey-Kellogg C. Hit-and-run, hit-and-stay, and commensal bacteria present different peptide content when viewed from the perspective of the T cell. Vaccine 2015;33:6922-9. [PMID: 26428457 DOI: 10.1016/j.vaccine.2015.08.099] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
21 Zhu J, Kim J, Xiao X, Wang Y, Luo D, Jiang S, Chen R, Xu L, Zhang H, Moise L, Gutierrez AH, De Groot AS, Xiao G, Schoggins JW, Zhan X, Wang T, Xie Y. The immune vulnerability landscape of the 2019 Novel Coronavirus, SARS-CoV-2. bioRxiv 2020:2020. [PMID: 32908981 DOI: 10.1101/2020.02.08.939553] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
22 De Groot AS. Do Tregitopes have the potential to impact the current treatment landscape of autoimmune diseases? Expert Review of Clinical Immunology 2014;9:1155-7. [DOI: 10.1586/1744666x.2013.858602] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
23 Ong E, Huang X, Pearce R, Zhang Y, He Y. Rational Design of SARS-CoV-2 Spike Glycoproteins To Increase Immunogenicity By T Cell Epitope Engineering. bioRxiv 2020:2020. [PMID: 32817949 DOI: 10.1101/2020.08.14.251496] [Reference Citation Analysis]
24 Kruiswijk C, Richard G, Salverda MLM, Hindocha P, Martin WD, De Groot AS, Van Riet E. In silico identification and modification of T cell epitopes in pertussis antigens associated with tolerance. Hum Vaccin Immunother 2020;16:277-85. [PMID: 31951773 DOI: 10.1080/21645515.2019.1703453] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
25 Hoeppli RE, MacDonald KG, Levings MK, Cook L. How antigen specificity directs regulatory T-cell function: self, foreign and engineered specificity. HLA 2016;88:3-13. [PMID: 27256587 DOI: 10.1111/tan.12822] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
26 Bandrick M, Gutiérrez AH, Desai P, Rincon G, Martin WD, Terry FE, De Groot AS, Foss DL. T cell epitope content comparison (EpiCC) analysis demonstrates a bivalent PCV2 vaccine has greater T cell epitope overlap with field strains than monovalent PCV2 vaccines. Vet Immunol Immunopathol 2020;223:110034. [PMID: 32278900 DOI: 10.1016/j.vetimm.2020.110034] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
27 Eickhoff CS, Van Aartsen D, Terry FE, Meymandi SK, Traina MM, Hernandez S, Martin WD, Moise L, De Groot AS, Hoft DF. An immunoinformatic approach for identification of Trypanosoma cruzi HLA-A2-restricted CD8(+) T cell epitopes. Hum Vaccin Immunother 2015;11:2322-8. [PMID: 26107442 DOI: 10.1080/21645515.2015.1061160] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
28 Moise L, Gutierrez A, Kibria F, Martin R, Tassone R, Liu R, Terry F, Martin B, De Groot AS. iVAX: An integrated toolkit for the selection and optimization of antigens and the design of epitope-driven vaccines. Hum Vaccin Immunother 2015;11:2312-21. [PMID: 26155959 DOI: 10.1080/21645515.2015.1061159] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 8.7] [Reference Citation Analysis]
29 Ong E, Huang X, Pearce R, Zhang Y, He Y. Computational design of SARS-CoV-2 spike glycoproteins to increase immunogenicity by T cell epitope engineering. Comput Struct Biotechnol J 2021;19:518-29. [PMID: 33398234 DOI: 10.1016/j.csbj.2020.12.039] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
30 Maine CJ, Richard G, Spasova DS, Miyake-Stoner SJ, Sparks J, Moise L, Sullivan RP, Garijo O, Choz M, Crouse JM, Aguilar A, Olesiuk MD, Lyons K, Salvador K, Blomgren M, DeHart JL, Kamrud KI, Berdugo G, De Groot AS, Wang NS, Aliahmad P. Self-Replicating RNAs Drive Protective Anti-tumor T Cell Responses to Neoantigen Vaccine Targets in a Combinatorial Approach. Mol Ther 2021;29:1186-98. [PMID: 33278563 DOI: 10.1016/j.ymthe.2020.11.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Buonaguro L, Tagliamonte M. Selecting Target Antigens for Cancer Vaccine Development. Vaccines (Basel) 2020;8:E615. [PMID: 33080888 DOI: 10.3390/vaccines8040615] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
32 Ahmed SS, Ellis RW, Rappuoli R. Technologies for Making New Vaccines. Plotkin's Vaccines. Elsevier; 2018. pp. 1283-1304.e7. [DOI: 10.1016/b978-0-323-35761-6.00066-3] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
33 Moise L, Gutiérrez AH, Khan S, Tan S, Ardito M, Martin WD, De Groot AS. New Immunoinformatics Tools for Swine: Designing Epitope-Driven Vaccines, Predicting Vaccine Efficacy, and Making Vaccines on Demand. Front Immunol 2020;11:563362. [PMID: 33123135 DOI: 10.3389/fimmu.2020.563362] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 De Groot AS, Einck L, Moise L, Chambers M, Ballantyne J, Malone RW, Ardito M, Martin W. Making vaccines "on demand": a potential solution for emerging pathogens and biodefense? Hum Vaccin Immunother 2013;9:1877-84. [PMID: 23877094 DOI: 10.4161/hv.25611] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
35 Gutiérrez AH, Rapp-Gabrielson VJ, Terry FE, Loving CL, Moise L, Martin WD, De Groot AS. T-cell epitope content comparison (EpiCC) of swine H1 influenza A virus hemagglutinin. Influenza Other Respir Viruses 2017;11:531-42. [PMID: 29054116 DOI: 10.1111/irv.12513] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
36 Tan S, Gutiérrez AH, Gauger PC, Opriessnig T, Bahl J, Moise L, De Groot AS. Quantifying the Persistence of Vaccine-Related T Cell Epitopes in Circulating Swine Influenza A Strains from 2013-2017. Vaccines (Basel) 2021;9:468. [PMID: 34066605 DOI: 10.3390/vaccines9050468] [Reference Citation Analysis]
37 De Groot AS, Kazi ZB, Martin RF, Terry FE, Desai AK, Martin WD, Kishnani PS. HLA- and genotype-based risk assessment model to identify infantile onset pompe disease patients at high-risk of developing significant anti-drug antibodies (ADA). Clin Immunol 2019;200:66-70. [PMID: 30711607 DOI: 10.1016/j.clim.2019.01.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
38 Abdel-Hady KM, Gutierrez AH, Terry F, Desrosiers J, De Groot AS, Azzazy HM. Identification and retrospective validation of T-cell epitopes in the hepatitis C virus genotype 4 proteome: an accelerated approach toward epitope-driven vaccine development. Hum Vaccin Immunother 2014;10:2366-77. [PMID: 25424944 DOI: 10.4161/hv.29177] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
39 van Riet E, Ainai A, Suzuki T, Kersten G, Hasegawa H. Combatting infectious diseases; nanotechnology as a platform for rational vaccine design. Advanced Drug Delivery Reviews 2014;74:28-34. [DOI: 10.1016/j.addr.2014.05.011] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
40 Scholzen A, Richard G, Moise L, Baeten LA, Reeves PM, Martin WD, Brauns TA, Boyle CM, Raju Paul S, Bucala R, Bowen RA, Garritsen A, De Groot AS, Sluder AE, Poznansky MC. Promiscuous Coxiella burnetii CD4 Epitope Clusters Associated With Human Recall Responses Are Candidates for a Novel T-Cell Targeted Multi-Epitope Q Fever Vaccine. Front Immunol 2019;10:207. [PMID: 30828331 DOI: 10.3389/fimmu.2019.00207] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
41 Leblanc P, Moise L, Luza C, Chantaralawan K, Lezeau L, Yuan J, Field M, Richer D, Boyle C, Martin WD, Fishman JB, Berg EA, Baker D, Zeigler B, Mais DE, Taylor W, Coleman R, Warren HS, Gelfand JA, De Groot AS, Brauns T, Poznansky MC. VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever. Hum Vaccin Immunother 2014;10:3022-38. [PMID: 25483693 DOI: 10.4161/hv.34413] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
42 Li X, An Y, Liao J, Xiao L, Swanson M, Martinez-Fonts K, Pavon JA, Sherer EC, Jawa V, Wang F, Gao X, Letarte S, Richardson DD. Identification and characterization of a residual host cell protein hexosaminidase B associated with N-glycan degradation during the stability study of a therapeutic recombinant monoclonal antibody product. Biotechnol Prog 2021;:e3128. [PMID: 33476097 DOI: 10.1002/btpr.3128] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
43 Mendes MF, Antunes DA, Rigo MM, Sinigaglia M, Vieira GF. Improved structural method for T-cell cross-reactivity prediction. Mol Immunol 2015;67:303-10. [PMID: 26141239 DOI: 10.1016/j.molimm.2015.06.017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
44 Noe AR, Terry FE, Schanen BC, Sassano E, Hindocha P, Phares TW, Moise L, Christen JM, Tucker KD, Kotraiah V, Drake DR 3rd, Martin WD, De Groot AS, Gutierrez GM. Bridging Computational Vaccinology and Vaccine Development Through Systematic Identification, Characterization, and Downselection of Conserved and Variable Circumsporozoite Protein CD4 T Cell Epitopes From Diverse Plasmodium falciparum Strains. Front Immunol 2021;12:689920. [PMID: 34168657 DOI: 10.3389/fimmu.2021.689920] [Reference Citation Analysis]
45 Richard G, Princiotta MF, Bridon D, Martin WD, Steinberg GD, De Groot AS. Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy. Expert Rev Vaccines 2021;:1-12. [PMID: 34882038 DOI: 10.1080/14760584.2022.2012456] [Reference Citation Analysis]
46 Dingman R, Balu-Iyer SV. Immunogenicity of Protein Pharmaceuticals. J Pharm Sci 2019;108:1637-54. [PMID: 30599169 DOI: 10.1016/j.xphs.2018.12.014] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 7.8] [Reference Citation Analysis]
47 Bailey-Kellogg C, Gutiérrez AH, Moise L, Terry F, Martin WD, De Groot AS. CHOPPI: a web tool for the analysis of immunogenicity risk from host cell proteins in CHO-based protein production. Biotechnol Bioeng 2014;111:2170-82. [PMID: 24888712 DOI: 10.1002/bit.25286] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
48 Terry FE, Moise L, Martin RF, Torres M, Pilotte N, Williams SA, De Groot AS. Time for T? Immunoinformatics addresses vaccine design for neglected tropical and emerging infectious diseases. Expert Rev Vaccines 2015;14:21-35. [PMID: 25193104 DOI: 10.1586/14760584.2015.955478] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
49 Jawa V, Terry F, Gokemeijer J, Mitra-Kaushik S, Roberts BJ, Tourdot S, De Groot AS. T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation-Updated Consensus and Review 2020. Front Immunol 2020;11:1301. [PMID: 32695107 DOI: 10.3389/fimmu.2020.01301] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
50 van de Garde MDB, van Westen E, Poelen MCM, Rots NY, van Els CACM. Prediction and Validation of Immunogenic Domains of Pneumococcal Proteins Recognized by Human CD4+ T Cells. Infect Immun 2019;87:e00098-19. [PMID: 30910792 DOI: 10.1128/IAI.00098-19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
51 De Groot AS, Moise L, Liu R, Gutierrez AH, Tassone R, Bailey-Kellogg C, Martin W. Immune camouflage: relevance to vaccines and human immunology. Hum Vaccin Immunother 2014;10:3570-5. [PMID: 25483703 DOI: 10.4161/hv.36134] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
52 Moise L, Beseme S, Tassone R, Liu R, Kibria F, Terry F, Martin W, De Groot AS. T cell epitope redundancy: cross-conservation of the TCR face between pathogens and self and its implications for vaccines and autoimmunity. Expert Rev Vaccines 2016;15:607-17. [PMID: 26588466 DOI: 10.1586/14760584.2016.1123098] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
53 Moise L, Terry F, Gutierrez AH, Tassone R, Losikoff P, Gregory SH, Bailey-Kellogg C, Martin WD, De Groot AS. Smarter vaccine design will circumvent regulatory T cell-mediated evasion in chronic HIV and HCV infection. Front Microbiol 2014;5:502. [PMID: 25339942 DOI: 10.3389/fmicb.2014.00502] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
54 Reeves PM, Paul SR, Sluder AE, Brauns TA, Poznansky MC. Q-vaxcelerate: A distributed development approach for a new Coxiella burnetii vaccine. Hum Vaccin Immunother 2017;13:2977-81. [PMID: 28933682 DOI: 10.1080/21645515.2017.1371377] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
55 Cavalluzzo B, Ragone C, Mauriello A, Petrizzo A, Manolio C, Caporale A, Vitagliano L, Ruvo M, Buonaguro L, Tagliamonte M. Identification and characterization of heteroclitic peptides in TCR-binding positions with improved HLA-binding efficacy. J Transl Med 2021;19:89. [PMID: 33637105 DOI: 10.1186/s12967-021-02757-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
56 Hewitt JS, Karuppannan AK, Tan S, Gauger P, Halbur PG, Gerber PF, De Groot AS, Moise L, Opriessnig T. A prime-boost concept using a T-cell epitope-driven DNA vaccine followed by a whole virus vaccine effectively protected pigs in the pandemic H1N1 pig challenge model. Vaccine 2019;37:4302-9. [PMID: 31248687 DOI: 10.1016/j.vaccine.2019.06.044] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
57 Shattuck WM, Dyer MC, Desrosiers J, Fast LD, Terry FE, Martin WD, Moise L, De Groot AS, Mather TN. Partial pathogen protection by tick-bite sensitization and epitope recognition in peptide-immunized HLA DR3 transgenic mice. Hum Vaccin Immunother 2014;10:3048-59. [PMID: 25517089 DOI: 10.4161/21645515.2014.985498] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
58 Winterling K, Martin WD, De Groot AS, Daufenbach J, Kistner S, Schüttrumpf J. Development of a novel fully functional coagulation factor VIII with reduced immunogenicity utilizing an in silico prediction and deimmunization approach. J Thromb Haemost 2021;19:2161-70. [PMID: 34060724 DOI: 10.1111/jth.15413] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Gokemeijer J, Jawa V, Mitra-Kaushik S. How Close Are We to Profiling Immunogenicity Risk Using In Silico Algorithms and In Vitro Methods?: an Industry Perspective. AAPS J 2017;19:1587-92. [PMID: 28971356 DOI: 10.1208/s12248-017-0143-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
60 Meyers LM, Gutiérrez AH, Boyle CM, Terry F, McGonnigal BG, Salazar A, Princiotta MF, Martin WD, De Groot AS, Moise L. Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation. NPJ Vaccines 2021;6:71. [PMID: 33986292 DOI: 10.1038/s41541-021-00331-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 De Groot AS, De Groot P, He Y. ICoVax 2013: the 3rd ISV Pre-conference Computational Vaccinology Workshop. BMC Bioinformatics 2014;15 Suppl 4:I1. [PMID: 25104130 DOI: 10.1186/1471-2105-15-S4-I1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
62 Hrdinová J, Verbij FC, Kaijen PHP, Hartholt RB, van Alphen F, Lardy N, Ten Brinke A, Vanhoorelbeke K, Hindocha PJ, De Groot AS, Meijer AB, Voorberg J, Peyron I. Mass spectrometry-assisted identification of ADAMTS13-derived peptides presented on HLA-DR and HLA-DQ. Haematologica 2018;103:1083-92. [PMID: 29567779 DOI: 10.3324/haematol.2017.179119] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
63 van Westen E, Poelen MCM, van den Dobbelsteen GPJM, Oloo EO, Ochs MM, Rots NY, van Els CACM. Immunodominance in T cell responses elicited against different domains of detoxified pneumolysin PlyD1. PLoS One 2018;13:e0193650. [PMID: 29509778 DOI: 10.1371/journal.pone.0193650] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
64 De Groot AS, Rosenberg AS, Miah SMS, Skowron G, Roberts BJ, Lélias S, Terry FE, Martin WD. Identification of a potent regulatory T cell epitope in factor V that modulates CD4+ and CD8+ memory T cell responses. Clin Immunol 2021;224:108661. [PMID: 33412295 DOI: 10.1016/j.clim.2020.108661] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
65 Kotraiah V, Phares TW, Terry FE, Hindocha P, Silk SE, Nielsen CM, Moise L, Tucker KD, Ashfield R, Martin WD, De Groot AS, Draper SJ, Gutierrez GM, Noe AR. Identification and Immune Assessment of T Cell Epitopes in Five Plasmodium falciparum Blood Stage Antigens to Facilitate Vaccine Candidate Selection and Optimization. Front Immunol 2021;12:690348. [PMID: 34305923 DOI: 10.3389/fimmu.2021.690348] [Reference Citation Analysis]
66 Moise L, Terry F, Ardito M, Tassone R, Latimer H, Boyle C, Martin WD, De Groot AS. Universal H1N1 influenza vaccine development: identification of consensus class II hemagglutinin and neuraminidase epitopes derived from strains circulating between 1980 and 2011. Hum Vaccin Immunother 2013;9:1598-607. [PMID: 23846304 DOI: 10.4161/hv.25598] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]